Completed
Foscarnet-Ganciclovir CMV Retinitis Trial
Led by Johns Hopkins Bloomberg School of Public Health · Updated on 2015-10-22
234
Participants Needed
N/A
Research Sites
N/A
Total Duration
On this page
Sponsors
J
Johns Hopkins Bloomberg School of Public Health
Lead Sponsor
N
National Eye Institute (NEI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
To evaluate the relative safety and efficacy of ganciclovir and foscarnet as initial treatment of patients with cytomegalovirus (CMV) retinitis.
CONDITIONS
Brief Title
Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT)
Who Can Participate
Eligibility Criteria
Inclusion criteria:
- CMV retinitis in one or both eyes
- At least 1/4 disk are of one CMV lesion photographable
- Diagnosis of AIDS as defined by Center for Disease Control criteria or documented HIV infection
- Age 13 and greater
- Visual acuity ≥ 3/200 in at least one eye diagnosed with CMV retinitis
- Absolute neutrophil count ≥ 1,000 cells/µl
- Platelet ≥ 25,000 cells/µl
- Serum creatinine ≥ 2.0 mg/dl
- Karnofsky score ≥ 60
- Informed consent
Exclusion criteria:
- Previous treatment of CMV retinitis
- Treatment with anti-CMV therapy for an extra-ocular CMV infection currently or in the past 28 days
- Known or suspected allergy to study drugs
- Pregnant or Lactating
Trial Site Locations
Site Locations not provided
Location information for this trial is currently unavailable.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here